{
    "clinical_study": {
        "@rank": "115854", 
        "acronym": "BEVPAC", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm B: Paclitaxel 80mg/m2 iv weekly."
            }
        ], 
        "brief_summary": {
            "textblock": "To explore molecular biomarkers and/or gene expression signatures that predict response to\n      bevacizumab given in combination with paclitaxel as first line therapy in HER2 negative\n      metastatic breast cancer (MBC)."
        }, 
        "brief_title": "A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, randomized, 2-arm, open-label, single-center, phase II trial. A total\n      of 30 patients will be included during a period of 2 years.\n\n      The study will be initiated with a non-randomized, feasibility stage including ten patients\n      who will be treated with bevacizumab and paclitaxel, in order to determine the safety of\n      metastatic tumor biopsies during therapy with bevacizumab.\n\n      In the second phase, patients will be randomized (1:1) between two treatment arms: A.\n      Bevacizumab + paclitaxel and B. Paclitaxel"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18-70 years.\n\n          2. Performance status ECOG 0-2.\n\n          3. Clinically and / or radiologically proven stage IV or recurrent HER2 negative breast\n             cancer.\n\n          4. At least one tumor lesion accessible for biopsy. This lesion may not have been\n             treated previously with irradiation.\n\n          5. Clinically and/or radiographically documented measurable disease according to RECIST\n             v1.1 criteria. At least one site of disease must be unidimensionally measurable as\n             follows:\n\n               1. CT-scan, physical exam \u2265 10 mm} Chest X-ray \u2265 20 mm }see Eisenhauer et al. for\n                  more details\n\n               2. Lymph node short axis \u2265 15 mm }\n\n               3. All radiology studies must be performed within 28 days prior to registration (35\n                  days if negative).\n\n          6. Adequate bone-marrow, hepatic and renal function defined as laboratory tests within 7\n             days prior to enrollment:\n\n               1. Haematology: Absolute granulocytes > 1.5 x 109/L Platelets > 100 x 109/L\n\n               2. Biochemistry:Bilirubin within normal limits Serum creatinine within normal\n                  limits\n\n          7. APTT and INR within normal limits within 7 days prior to enrollment.\n\n          8. Adequate cardiac function with Left Ventricular  Ejection Fraction (LVEF) within\n             normal limits determined by echocardiogram or  MUGA within 28 days prior to\n             inclusion.\n\n          9. Written informed consent must be given.\n\n        Exclusion Criteria:\n\n          1. Previous systemic treatment for MBC.\n\n          2. Major surgery less than 28 days prior to enrollment.\n\n          3. Concurrent malignancy of any site, except adequately controlled limited basal cell\n             carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix.\n\n          4. Bleeding diathesis, history of thromboembolic disease, or ongoing treatment with\n             warfarin, heparin analogs or antiplatelet drugs.\n\n          5. Major cardiac comorbidity.\n\n          6. Previous treatment with bevacizumab.\n\n          7. Previous allergic reaction to taxane analogs.\n\n          8. Ongoing pregnancy or lactation.\n\n          9. Any psychological, familial, sociological or geographical condition potentially\n             hampering compliance with the study protocol and follow-up schedule; those conditions\n             should be discussed with the patient before registration in the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722968", 
            "org_study_id": "EudraCT no: 2012-003743-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "80mg/m2 iv weekly", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paxene", 
                    "Taxol"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Metastatic breast cancer", 
        "lastchanged_date": "May 20, 2013", 
        "location": {
            "contact": {
                "email": "theodoros.foukakis@ki.se", 
                "last_name": "Theodoros Foukakis, MD, PhD", 
                "phone": "+46 736896713"
            }, 
            "facility": {
                "address": {
                    "city": "Solna", 
                    "country": "Sweden", 
                    "state": "Stockholm", 
                    "zip": "17176"
                }, 
                "name": "Karolinska University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Mechanisms of Therapy Resistance in Patients With HER2-negative Metastatic Breast Cancer Treated With the Combination of Bevacizumab and Paclitaxel (BEVPAC).", 
        "other_outcome": [
            {
                "description": "To identify molecular changes in the tumor induced by the addition of bevacizumab to chemotherapy.", 
                "measure": "Molecular changes by bevacizumab", 
                "safety_issue": "No", 
                "time_frame": "After completion of the study which will take up to 3 years"
            }, 
            {
                "description": "To measure the efficacy of bevacizumab in combination with paclitaxel in HER2 negative MBC.", 
                "measure": "Efficacy of bevacizumab", 
                "safety_issue": "No", 
                "time_frame": "After completion of the study, After completion of the study, which will take up to 3 years"
            }
        ], 
        "overall_contact": {
            "email": "theodoros.foukakis@ki.se", 
            "last_name": "Theodoros Foukakis, MD, PhD", 
            "phone": "+46736896713"
        }, 
        "overall_official": [
            {
                "affiliation": "Karolinska University Hospital", 
                "last_name": "Theodoros Foukakis, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Karolinska University Hospital", 
                "last_name": "Jonas Bergh, Professor", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To explore molecular biomarkers and/or gene expression signatures that predict response to bevacizumab given in combination with paclitaxel as first line therapy in HER2 negative MBC.", 
            "measure": "Identification of molecular biomarkers", 
            "safety_issue": "No", 
            "time_frame": "After the study completion,After completion of the study, which will take up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722968"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska University Hospital", 
            "investigator_full_name": "Theodoros Foukakis", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "The safety objective of the study is to assess whether carrying out metastatic tissue biopsies during treatment with bevacizumab is safe. For this reason, the study will be initiated with a feasibility phase of 10 patients and will be continued to the randomized phase only if the study specific procedures prove to be safe.", 
            "measure": "Safety of metastatic biopsies during bevacizumab therapy", 
            "safety_issue": "Yes", 
            "time_frame": "continuous assessment and after inclusion of 10 patients, After completion of the study which will take up to 1 year"
        }, 
        "source": "Karolinska University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theodoros Foukakis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}